

Global Vector-Based RNAi Market Growth 2023-2029

<https://marketpublishers.com/r/G8E9C550730EEN.html>

Date: February 2023

Pages: 108

Price: US\$ 3,660.00 (Single User License)

ID: G8E9C550730EEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Vector-based RNAi (RNA interference) offers a system of treatment and disease management to decrease the inhibition of gene translation or expression, as well as it neutralizes the targeted mRNA molecules. Vector-based RNAi plays very important in cancer treatment, cancer is the top second cause of death across the globe. As well as a new development in vector-based RNAi such as small interfering RNAs (siRNA) and microRNAs (miRNA) can escalate the vector-based RNAi market growth. The challenging situation of FDA approval affecting on a number of new drugs launch, for instance, 2015 (41 drugs), while in 2016 (19 drugs) which are very less as compared with the previous year.

LPI (LP Information)' newest research report, the "Vector-Based RNAi Industry Forecast" looks at past sales and reviews total world Vector-Based RNAi sales in 2022, providing a comprehensive analysis by region and market sector of projected Vector-Based RNAi sales for 2023 through 2029. With Vector-Based RNAi sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Vector-Based RNAi industry.

This Insight Report provides a comprehensive analysis of the global Vector-Based RNAi landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Vector-Based RNAi portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Vector-Based RNAi market.

This Insight Report evaluates the key market trends, drivers, and affecting factors

shaping the global outlook for Vector-Based RNAi and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vector-Based RNAi.

The global Vector-Based RNAi market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Vector-Based RNAi is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Vector-Based RNAi is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Vector-Based RNAi is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Vector-Based RNAi players cover Merck & Co., Phio Pharmaceutical, Quark Pharmaceuticals, Thermo Fisher Scientific, Silence Therapeutics, Qiagen NV, Ionis Pharmaceutical, Dicerna Pharmaceuticals and Arrowhead Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Vector-Based RNAi market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

siRNA Design

siRNA Vectors

Custom siRNA Construction

Segmentation by application

Hospitals

Speciality Clinics

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Merck & Co.

Phio Pharmaceutical

Quark Pharmaceuticals

Thermo Fisher Scientific

Silence Therapeutics

Qiagen NV

Ionis Pharmaceutical

Dicerna Pharmaceuticals

Arrowhead Pharmaceuticals

Arcturus Therapeutics

Alnylam Pharmaceuticals

Key Questions Addressed in this Report

What is the 10-year outlook for the global Vector-Based RNAi market?

What factors are driving Vector-Based RNAi market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Vector-Based RNAi market opportunities vary by end market size?

How does Vector-Based RNAi break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Vector-Based RNAi Annual Sales 2018-2029
 - 2.1.2 World Current & Future Analysis for Vector-Based RNAi by Geographic Region, 2018, 2022 & 2029
 - 2.1.3 World Current & Future Analysis for Vector-Based RNAi by Country/Region, 2018, 2022 & 2029
- 2.2 Vector-Based RNAi Segment by Type
 - 2.2.1 siRNA Design
 - 2.2.2 siRNA Vectors
 - 2.2.3 Custom siRNA Construction
- 2.3 Vector-Based RNAi Sales by Type
 - 2.3.1 Global Vector-Based RNAi Sales Market Share by Type (2018-2023)
 - 2.3.2 Global Vector-Based RNAi Revenue and Market Share by Type (2018-2023)
 - 2.3.3 Global Vector-Based RNAi Sale Price by Type (2018-2023)
- 2.4 Vector-Based RNAi Segment by Application
 - 2.4.1 Hospitals
 - 2.4.2 Speciality Clinics
- 2.5 Vector-Based RNAi Sales by Application
 - 2.5.1 Global Vector-Based RNAi Sale Market Share by Application (2018-2023)
 - 2.5.2 Global Vector-Based RNAi Revenue and Market Share by Application (2018-2023)
 - 2.5.3 Global Vector-Based RNAi Sale Price by Application (2018-2023)

3 GLOBAL VECTOR-BASED RNAI BY COMPANY

- 3.1 Global Vector-Based RNAi Breakdown Data by Company
 - 3.1.1 Global Vector-Based RNAi Annual Sales by Company (2018-2023)
 - 3.1.2 Global Vector-Based RNAi Sales Market Share by Company (2018-2023)
- 3.2 Global Vector-Based RNAi Annual Revenue by Company (2018-2023)
 - 3.2.1 Global Vector-Based RNAi Revenue by Company (2018-2023)
 - 3.2.2 Global Vector-Based RNAi Revenue Market Share by Company (2018-2023)
- 3.3 Global Vector-Based RNAi Sale Price by Company
- 3.4 Key Manufacturers Vector-Based RNAi Producing Area Distribution, Sales Area, Product Type
 - 3.4.1 Key Manufacturers Vector-Based RNAi Product Location Distribution
 - 3.4.2 Players Vector-Based RNAi Products Offered
- 3.5 Market Concentration Rate Analysis
 - 3.5.1 Competition Landscape Analysis
 - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR VECTOR-BASED RNAI BY GEOGRAPHIC REGION

- 4.1 World Historic Vector-Based RNAi Market Size by Geographic Region (2018-2023)
 - 4.1.1 Global Vector-Based RNAi Annual Sales by Geographic Region (2018-2023)
 - 4.1.2 Global Vector-Based RNAi Annual Revenue by Geographic Region (2018-2023)
- 4.2 World Historic Vector-Based RNAi Market Size by Country/Region (2018-2023)
 - 4.2.1 Global Vector-Based RNAi Annual Sales by Country/Region (2018-2023)
 - 4.2.2 Global Vector-Based RNAi Annual Revenue by Country/Region (2018-2023)
- 4.3 Americas Vector-Based RNAi Sales Growth
- 4.4 APAC Vector-Based RNAi Sales Growth
- 4.5 Europe Vector-Based RNAi Sales Growth
- 4.6 Middle East & Africa Vector-Based RNAi Sales Growth

5 AMERICAS

- 5.1 Americas Vector-Based RNAi Sales by Country
 - 5.1.1 Americas Vector-Based RNAi Sales by Country (2018-2023)
 - 5.1.2 Americas Vector-Based RNAi Revenue by Country (2018-2023)
- 5.2 Americas Vector-Based RNAi Sales by Type
- 5.3 Americas Vector-Based RNAi Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Vector-Based RNAi Sales by Region

6.1.1 APAC Vector-Based RNAi Sales by Region (2018-2023)

6.1.2 APAC Vector-Based RNAi Revenue by Region (2018-2023)

6.2 APAC Vector-Based RNAi Sales by Type

6.3 APAC Vector-Based RNAi Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Vector-Based RNAi by Country

7.1.1 Europe Vector-Based RNAi Sales by Country (2018-2023)

7.1.2 Europe Vector-Based RNAi Revenue by Country (2018-2023)

7.2 Europe Vector-Based RNAi Sales by Type

7.3 Europe Vector-Based RNAi Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Vector-Based RNAi by Country

8.1.1 Middle East & Africa Vector-Based RNAi Sales by Country (2018-2023)

8.1.2 Middle East & Africa Vector-Based RNAi Revenue by Country (2018-2023)

8.2 Middle East & Africa Vector-Based RNAi Sales by Type

8.3 Middle East & Africa Vector-Based RNAi Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Vector-Based RNAi

10.3 Manufacturing Process Analysis of Vector-Based RNAi

10.4 Industry Chain Structure of Vector-Based RNAi

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Vector-Based RNAi Distributors

11.3 Vector-Based RNAi Customer

12 WORLD FORECAST REVIEW FOR VECTOR-BASED RNAI BY GEOGRAPHIC REGION

12.1 Global Vector-Based RNAi Market Size Forecast by Region

12.1.1 Global Vector-Based RNAi Forecast by Region (2024-2029)

12.1.2 Global Vector-Based RNAi Annual Revenue Forecast by Region (2024-2029)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Vector-Based RNAi Forecast by Type

12.7 Global Vector-Based RNAi Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Merck & Co.

13.1.1 Merck & Co. Company Information

13.1.2 Merck & Co. Vector-Based RNAi Product Portfolios and Specifications

13.1.3 Merck & Co. Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)

13.1.4 Merck & Co. Main Business Overview

13.1.5 Merck & Co. Latest Developments

13.2 Phio Pharmaceutical

13.2.1 Phio Pharmaceutical Company Information

13.2.2 Phio Pharmaceutical Vector-Based RNAi Product Portfolios and Specifications

13.2.3 Phio Pharmaceutical Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)

13.2.4 Phio Pharmaceutical Main Business Overview

13.2.5 Phio Pharmaceutical Latest Developments

13.3 Quark Pharmaceuticals

13.3.1 Quark Pharmaceuticals Company Information

13.3.2 Quark Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications

13.3.3 Quark Pharmaceuticals Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)

13.3.4 Quark Pharmaceuticals Main Business Overview

13.3.5 Quark Pharmaceuticals Latest Developments

13.4 Thermo Fisher Scientific

13.4.1 Thermo Fisher Scientific Company Information

13.4.2 Thermo Fisher Scientific Vector-Based RNAi Product Portfolios and Specifications

13.4.3 Thermo Fisher Scientific Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)

13.4.4 Thermo Fisher Scientific Main Business Overview

13.4.5 Thermo Fisher Scientific Latest Developments

13.5 Silence Therapeutics

13.5.1 Silence Therapeutics Company Information

13.5.2 Silence Therapeutics Vector-Based RNAi Product Portfolios and Specifications

13.5.3 Silence Therapeutics Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)

- 13.5.4 Silence Therapeutics Main Business Overview
- 13.5.5 Silence Therapeutics Latest Developments
- 13.6 Qiagen NV
 - 13.6.1 Qiagen NV Company Information
 - 13.6.2 Qiagen NV Vector-Based RNAi Product Portfolios and Specifications
 - 13.6.3 Qiagen NV Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.6.4 Qiagen NV Main Business Overview
 - 13.6.5 Qiagen NV Latest Developments
- 13.7 Ionis Pharmaceutical
 - 13.7.1 Ionis Pharmaceutical Company Information
 - 13.7.2 Ionis Pharmaceutical Vector-Based RNAi Product Portfolios and Specifications
 - 13.7.3 Ionis Pharmaceutical Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.7.4 Ionis Pharmaceutical Main Business Overview
 - 13.7.5 Ionis Pharmaceutical Latest Developments
- 13.8 Dicerna Pharmaceuticals
 - 13.8.1 Dicerna Pharmaceuticals Company Information
 - 13.8.2 Dicerna Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications
 - 13.8.3 Dicerna Pharmaceuticals Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.8.4 Dicerna Pharmaceuticals Main Business Overview
 - 13.8.5 Dicerna Pharmaceuticals Latest Developments
- 13.9 Arrowhead Pharmaceuticals
 - 13.9.1 Arrowhead Pharmaceuticals Company Information
 - 13.9.2 Arrowhead Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications
 - 13.9.3 Arrowhead Pharmaceuticals Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.9.4 Arrowhead Pharmaceuticals Main Business Overview
 - 13.9.5 Arrowhead Pharmaceuticals Latest Developments
- 13.10 Arcturus Therapeutics
 - 13.10.1 Arcturus Therapeutics Company Information
 - 13.10.2 Arcturus Therapeutics Vector-Based RNAi Product Portfolios and Specifications
 - 13.10.3 Arcturus Therapeutics Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.10.4 Arcturus Therapeutics Main Business Overview

13.10.5 Arcturus Therapeutics Latest Developments

13.11 Alnylam Pharmaceuticals

13.11.1 Alnylam Pharmaceuticals Company Information

13.11.2 Alnylam Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications

13.11.3 Alnylam Pharmaceuticals Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)

13.11.4 Alnylam Pharmaceuticals Main Business Overview

13.11.5 Alnylam Pharmaceuticals Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Vector-Based RNAi Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)
- Table 2. Vector-Based RNAi Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)
- Table 3. Major Players of siRNA Design
- Table 4. Major Players of siRNA Vectors
- Table 5. Major Players of Custom siRNA Construction
- Table 6. Global Vector-Based RNAi Sales by Type (2018-2023) & (K Units)
- Table 7. Global Vector-Based RNAi Sales Market Share by Type (2018-2023)
- Table 8. Global Vector-Based RNAi Revenue by Type (2018-2023) & (\$ million)
- Table 9. Global Vector-Based RNAi Revenue Market Share by Type (2018-2023)
- Table 10. Global Vector-Based RNAi Sale Price by Type (2018-2023) & (US\$/Unit)
- Table 11. Global Vector-Based RNAi Sales by Application (2018-2023) & (K Units)
- Table 12. Global Vector-Based RNAi Sales Market Share by Application (2018-2023)
- Table 13. Global Vector-Based RNAi Revenue by Application (2018-2023)
- Table 14. Global Vector-Based RNAi Revenue Market Share by Application (2018-2023)
- Table 15. Global Vector-Based RNAi Sale Price by Application (2018-2023) & (US\$/Unit)
- Table 16. Global Vector-Based RNAi Sales by Company (2018-2023) & (K Units)
- Table 17. Global Vector-Based RNAi Sales Market Share by Company (2018-2023)
- Table 18. Global Vector-Based RNAi Revenue by Company (2018-2023) (\$ Millions)
- Table 19. Global Vector-Based RNAi Revenue Market Share by Company (2018-2023)
- Table 20. Global Vector-Based RNAi Sale Price by Company (2018-2023) & (US\$/Unit)
- Table 21. Key Manufacturers Vector-Based RNAi Producing Area Distribution and Sales Area
- Table 22. Players Vector-Based RNAi Products Offered
- Table 23. Vector-Based RNAi Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
- Table 24. New Products and Potential Entrants
- Table 25. Mergers & Acquisitions, Expansion
- Table 26. Global Vector-Based RNAi Sales by Geographic Region (2018-2023) & (K Units)
- Table 27. Global Vector-Based RNAi Sales Market Share Geographic Region (2018-2023)

Table 28. Global Vector-Based RNAi Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 29. Global Vector-Based RNAi Revenue Market Share by Geographic Region (2018-2023)

Table 30. Global Vector-Based RNAi Sales by Country/Region (2018-2023) & (K Units)

Table 31. Global Vector-Based RNAi Sales Market Share by Country/Region (2018-2023)

Table 32. Global Vector-Based RNAi Revenue by Country/Region (2018-2023) & (\$ millions)

Table 33. Global Vector-Based RNAi Revenue Market Share by Country/Region (2018-2023)

Table 34. Americas Vector-Based RNAi Sales by Country (2018-2023) & (K Units)

Table 35. Americas Vector-Based RNAi Sales Market Share by Country (2018-2023)

Table 36. Americas Vector-Based RNAi Revenue by Country (2018-2023) & (\$ Millions)

Table 37. Americas Vector-Based RNAi Revenue Market Share by Country (2018-2023)

Table 38. Americas Vector-Based RNAi Sales by Type (2018-2023) & (K Units)

Table 39. Americas Vector-Based RNAi Sales by Application (2018-2023) & (K Units)

Table 40. APAC Vector-Based RNAi Sales by Region (2018-2023) & (K Units)

Table 41. APAC Vector-Based RNAi Sales Market Share by Region (2018-2023)

Table 42. APAC Vector-Based RNAi Revenue by Region (2018-2023) & (\$ Millions)

Table 43. APAC Vector-Based RNAi Revenue Market Share by Region (2018-2023)

Table 44. APAC Vector-Based RNAi Sales by Type (2018-2023) & (K Units)

Table 45. APAC Vector-Based RNAi Sales by Application (2018-2023) & (K Units)

Table 46. Europe Vector-Based RNAi Sales by Country (2018-2023) & (K Units)

Table 47. Europe Vector-Based RNAi Sales Market Share by Country (2018-2023)

Table 48. Europe Vector-Based RNAi Revenue by Country (2018-2023) & (\$ Millions)

Table 49. Europe Vector-Based RNAi Revenue Market Share by Country (2018-2023)

Table 50. Europe Vector-Based RNAi Sales by Type (2018-2023) & (K Units)

Table 51. Europe Vector-Based RNAi Sales by Application (2018-2023) & (K Units)

Table 52. Middle East & Africa Vector-Based RNAi Sales by Country (2018-2023) & (K Units)

Table 53. Middle East & Africa Vector-Based RNAi Sales Market Share by Country (2018-2023)

Table 54. Middle East & Africa Vector-Based RNAi Revenue by Country (2018-2023) & (\$ Millions)

Table 55. Middle East & Africa Vector-Based RNAi Revenue Market Share by Country (2018-2023)

Table 56. Middle East & Africa Vector-Based RNAi Sales by Type (2018-2023) & (K Units)

Table 57. Middle East & Africa Vector-Based RNAi Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Vector-Based RNAi
Table 59. Key Market Challenges & Risks of Vector-Based RNAi
Table 60. Key Industry Trends of Vector-Based RNAi
Table 61. Vector-Based RNAi Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Vector-Based RNAi Distributors List
Table 64. Vector-Based RNAi Customer List
Table 65. Global Vector-Based RNAi Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Vector-Based RNAi Revenue Forecast by Region (2024-2029) & (\$ millions)
Table 67. Americas Vector-Based RNAi Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Vector-Based RNAi Revenue Forecast by Country (2024-2029) & (\$ millions)
Table 69. APAC Vector-Based RNAi Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Vector-Based RNAi Revenue Forecast by Region (2024-2029) & (\$ millions)
Table 71. Europe Vector-Based RNAi Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Vector-Based RNAi Revenue Forecast by Country (2024-2029) & (\$ millions)
Table 73. Middle East & Africa Vector-Based RNAi Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Vector-Based RNAi Revenue Forecast by Country (2024-2029) & (\$ millions)
Table 75. Global Vector-Based RNAi Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Vector-Based RNAi Revenue Forecast by Type (2024-2029) & (\$ Millions)
Table 77. Global Vector-Based RNAi Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Vector-Based RNAi Revenue Forecast by Application (2024-2029) & (\$ Millions)
Table 79. Merck & Co. Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 80. Merck & Co. Vector-Based RNAi Product Portfolios and Specifications
Table 81. Merck & Co. Vector-Based RNAi Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 82. Merck & Co. Main Business

Table 83. Merck & Co. Latest Developments

Table 84. Phio Pharmaceutical Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors

Table 85. Phio Pharmaceutical Vector-Based RNAi Product Portfolios and Specifications

Table 86. Phio Pharmaceutical Vector-Based RNAi Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 87. Phio Pharmaceutical Main Business

Table 88. Phio Pharmaceutical Latest Developments

Table 89. Quark Pharmaceuticals Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors

Table 90. Quark Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications

Table 91. Quark Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 92. Quark Pharmaceuticals Main Business

Table 93. Quark Pharmaceuticals Latest Developments

Table 94. Thermo Fisher Scientific Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors

Table 95. Thermo Fisher Scientific Vector-Based RNAi Product Portfolios and Specifications

Table 96. Thermo Fisher Scientific Vector-Based RNAi Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 97. Thermo Fisher Scientific Main Business

Table 98. Thermo Fisher Scientific Latest Developments

Table 99. Silence Therapeutics Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors

Table 100. Silence Therapeutics Vector-Based RNAi Product Portfolios and Specifications

Table 101. Silence Therapeutics Vector-Based RNAi Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 102. Silence Therapeutics Main Business

Table 103. Silence Therapeutics Latest Developments

Table 104. Qiagen NV Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors

Table 105. Qiagen NV Vector-Based RNAi Product Portfolios and Specifications

Table 106. Qiagen NV Vector-Based RNAi Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 107. Qiagen NV Main Business

Table 108. Qiagen NV Latest Developments

Table 109. Ionis Pharmaceutical Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors

Table 110. Ionis Pharmaceutical Vector-Based RNAi Product Portfolios and Specifications

Table 111. Ionis Pharmaceutical Vector-Based RNAi Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 112. Ionis Pharmaceutical Main Business

Table 113. Ionis Pharmaceutical Latest Developments

Table 114. Dicerna Pharmaceuticals Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors

Table 115. Dicerna Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications

Table 116. Dicerna Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 117. Dicerna Pharmaceuticals Main Business

Table 118. Dicerna Pharmaceuticals Latest Developments

Table 119. Arrowhead Pharmaceuticals Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors

Table 120. Arrowhead Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications

Table 121. Arrowhead Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 122. Arrowhead Pharmaceuticals Main Business

Table 123. Arrowhead Pharmaceuticals Latest Developments

Table 124. Arcturus Therapeutics Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors

Table 125. Arcturus Therapeutics Vector-Based RNAi Product Portfolios and Specifications

Table 126. Arcturus Therapeutics Vector-Based RNAi Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 127. Arcturus Therapeutics Main Business

Table 128. Arcturus Therapeutics Latest Developments

Table 129. Alnylam Pharmaceuticals Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors

Table 130. Alnylam Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications

Table 131. Alnylam Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue (\$

Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 132. Alnylam Pharmaceuticals Main Business

Table 133. Alnylam Pharmaceuticals Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Vector-Based RNAi
- Figure 2. Vector-Based RNAi Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Vector-Based RNAi Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Vector-Based RNAi Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Vector-Based RNAi Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of siRNA Design
- Figure 10. Product Picture of siRNA Vectors
- Figure 11. Product Picture of Custom siRNA Construction
- Figure 12. Global Vector-Based RNAi Sales Market Share by Type in 2022
- Figure 13. Global Vector-Based RNAi Revenue Market Share by Type (2018-2023)
- Figure 14. Vector-Based RNAi Consumed in Hospitals
- Figure 15. Global Vector-Based RNAi Market: Hospitals (2018-2023) & (K Units)
- Figure 16. Vector-Based RNAi Consumed in Speciality Clinics
- Figure 17. Global Vector-Based RNAi Market: Speciality Clinics (2018-2023) & (K Units)
- Figure 18. Global Vector-Based RNAi Sales Market Share by Application (2022)
- Figure 19. Global Vector-Based RNAi Revenue Market Share by Application in 2022
- Figure 20. Vector-Based RNAi Sales Market by Company in 2022 (K Units)
- Figure 21. Global Vector-Based RNAi Sales Market Share by Company in 2022
- Figure 22. Vector-Based RNAi Revenue Market by Company in 2022 (\$ Million)
- Figure 23. Global Vector-Based RNAi Revenue Market Share by Company in 2022
- Figure 24. Global Vector-Based RNAi Sales Market Share by Geographic Region (2018-2023)
- Figure 25. Global Vector-Based RNAi Revenue Market Share by Geographic Region in 2022
- Figure 26. Americas Vector-Based RNAi Sales 2018-2023 (K Units)
- Figure 27. Americas Vector-Based RNAi Revenue 2018-2023 (\$ Millions)
- Figure 28. APAC Vector-Based RNAi Sales 2018-2023 (K Units)
- Figure 29. APAC Vector-Based RNAi Revenue 2018-2023 (\$ Millions)
- Figure 30. Europe Vector-Based RNAi Sales 2018-2023 (K Units)
- Figure 31. Europe Vector-Based RNAi Revenue 2018-2023 (\$ Millions)
- Figure 32. Middle East & Africa Vector-Based RNAi Sales 2018-2023 (K Units)
- Figure 33. Middle East & Africa Vector-Based RNAi Revenue 2018-2023 (\$ Millions)

Figure 34. Americas Vector-Based RNAi Sales Market Share by Country in 2022

Figure 35. Americas Vector-Based RNAi Revenue Market Share by Country in 2022

Figure 36. Americas Vector-Based RNAi Sales Market Share by Type (2018-2023)

Figure 37. Americas Vector-Based RNAi Sales Market Share by Application (2018-2023)

Figure 38. United States Vector-Based RNAi Revenue Growth 2018-2023 (\$ Millions)

Figure 39. Canada Vector-Based RNAi Revenue Growth 2018-2023 (\$ Millions)

Figure 40. Mexico Vector-Based RNAi Revenue Growth 2018-2023 (\$ Millions)

Figure 41. Brazil Vector-Based RNAi Revenue Growth 2018-2023 (\$ Millions)

Figure 42. APAC Vector-Based RNAi Sales Market Share by Region in 2022

Figure 43. APAC Vector-Based RNAi Revenue Market Share by Regions in 2022

Figure 44. APAC Vector-Based RNAi Sales Market Share by Type (2018-2023)

Figure 45. APAC Vector-Based RNAi Sales Market Share by Application (2018-2023)

Figure 46. China Vector-Based RNAi Revenue Growth 2018-2023 (\$ Millions)

Figure 47. Japan Vector-Based RNAi Revenue Growth 2018-2023 (\$ Millions)

Figure 48. South Korea Vector-Based RNAi Revenue Growth 2018-2023 (\$ Millions)

Figure 49. Southeast Asia Vector-Based RNAi Revenue Growth 2018-2023 (\$ Millions)

Figure 50. India Vector-Based RNAi Revenue Growth 2018-2023 (\$ Millions)

Figure 51. Australia Vector-Based RNAi Revenue Growth 2018-2023 (\$ Millions)

Figure 52. China Taiwan Vector-Based RNAi Revenue Growth 2018-2023 (\$ Millions)

Figure 53. Europe Vector-Based RNAi Sales Market Share by Country in 2022

Figure 54. Europe Vector-Based RNAi Revenue Market Share by Country in 2022

Figure 55. Europe Vector-Based RNAi Sales Market Share by Type (2018-2023)

Figure 56. Europe Vector-Based RNAi Sales Market Share by Application (2018-2023)

Figure 57. Germany Vector-Based RNAi Revenue Growth 2018-2023 (\$ Millions)

Figure 58. France Vector-Based RNAi Revenue Growth 2018-2023 (\$ Millions)

Figure 59. UK Vector-Based RNAi Revenue Growth 2018-2023 (\$ Millions)

Figure 60. Italy Vector-Based RNAi Revenue Growth 2018-2023 (\$ Millions)

Figure 61. Russia Vector-Based RNAi Revenue Growth 2018-2023 (\$ Millions)

Figure 62. Middle East & Africa Vector-Based RNAi Sales Market Share by Country in 2022

Figure 63. Middle East & Africa Vector-Based RNAi Revenue Market Share by Country in 2022

Figure 64. Middle East & Africa Vector-Based RNAi Sales Market Share by Type (2018-2023)

Figure 65. Middle East & Africa Vector-Based RNAi Sales Market Share by Application (2018-2023)

Figure 66. Egypt Vector-Based RNAi Revenue Growth 2018-2023 (\$ Millions)

Figure 67. South Africa Vector-Based RNAi Revenue Growth 2018-2023 (\$ Millions)

- Figure 68. Israel Vector-Based RNAi Revenue Growth 2018-2023 (\$ Millions)
- Figure 69. Turkey Vector-Based RNAi Revenue Growth 2018-2023 (\$ Millions)
- Figure 70. GCC Country Vector-Based RNAi Revenue Growth 2018-2023 (\$ Millions)
- Figure 71. Manufacturing Cost Structure Analysis of Vector-Based RNAi in 2022
- Figure 72. Manufacturing Process Analysis of Vector-Based RNAi
- Figure 73. Industry Chain Structure of Vector-Based RNAi
- Figure 74. Channels of Distribution
- Figure 75. Global Vector-Based RNAi Sales Market Forecast by Region (2024-2029)
- Figure 76. Global Vector-Based RNAi Revenue Market Share Forecast by Region (2024-2029)
- Figure 77. Global Vector-Based RNAi Sales Market Share Forecast by Type (2024-2029)
- Figure 78. Global Vector-Based RNAi Revenue Market Share Forecast by Type (2024-2029)
- Figure 79. Global Vector-Based RNAi Sales Market Share Forecast by Application (2024-2029)
- Figure 80. Global Vector-Based RNAi Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Vector-Based RNAi Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/G8E9C550730EEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8E9C550730EEN.html>